News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – December

AR-13324-CS208 Japan Phase 2 Study Topline Results

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 9, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 3, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 26, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 21, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
TOP